Unraveling Cancer — Dr. Matthew Gamble has been awarded $1.7 million over five years by the National Cancer Institute to study the relationship between macroH2A, a type of histone or protein around which long strands of DNA are spooled, which also is known to play a role in regulating gene activity and cancer. Because decreases in macroH2A have been associated with a variety of cancers, the Gamble laboratory will explore what precipitates this decrease and its downstream effects on cancer cell growth and survival. Additionally, these studies will inform ongoing efforts to fine-tune the use of PARP inhibitors in cancer treatment, which are known to interact with macroH2A. Dr. Gamble is assistant professor of molecular pharmacology.
Posted on: Monday, July 09, 2012